Merck KGaA gets FDA warning letter on EU plants; Sandoz nabs German rights to ED med;

@FiercePharma: Yet another Ben Venue fumble: Sanofi's Genzyme unit recalls leukemia drug made at Ohio plant--Bloomberg. News | Follow @FiercePharma

> The FDA has warned Merck KGaA on manufacturing failures at three separate facilities--two in Switzerland and the other in Italy--based on inspections conducted last summer. Report | Letter

> Novartis' ($NVS) Sandoz unit snapped up German marketing rights to the Apricus Biosciences erectile dysfunction drug Vitaros. News

> Canada's Paladin Labs reported higher profits for the fourth quarter, fueled by increased sales of several drugs, including the Plan B contraceptive. Article

> Actavis launched its version of the Alzheimer's drug Aricept in 8 of the EU's biggest markets, including Germany and France, as the drug's patent protection expired. Release

> A Harvard College activist group demonstrated at Merck's ($MRK) Cambridge research labs in an effort to persuade the drugmaker to join the Medicines Patent Pool for HIV drugs. Report

> GlaxoSmithKline's ($GSK) unit in India saw profits grow more than 18% for the quarter on growth in its specialty products and vaccines. Story

> GlaxoSmithKline has met vocal opposition to its plans for two wind turbines that would help power its site in Montrose, Scotland. News

> Teva Pharmaceutical Industries ($TEVA) CEO Shlomo Yanai said the company has contingency plans for Israeli manufacturing if "regional issues" caused disruption. Report

> Teva launched its version of the Alzheimer's drug Aricept in the U.K. as Eisai's patent on the treatment expires in that market. Article

Biotech News

@FierceBiotech: Researchers soup up patients' own immune cells to attack HIV. Story | Follow @FierceBiotech

@JohnCFierce: Fledgling Mnemosyne Pharmaceuticals snags a $5.4 million Series A for neuropsychiatric work. Release | Follow @JohnCFierce

@RyanMFierce: Not for those with arachnophobia: J&J to develop painkillers with spider venom in the mix. Article | Follow @RyanMFierce

@FierceMedDev: Edwards has received CE Mark for its EDWARDS INTUITY for those undergoing surgical aortic valve replacement. Release | Follow @FierceMedDev

> Bionor surges as PhIIb study revives big hopes for HIV vaccine. News

> J&J backs potential pain drugs derived from spider venom. Item

> Biotech startup Mnemosyne snags $5.4M A round for neuropsych R&D. Article

Vaccines News

> FDA says no to Novartis' Menveo vax for babies. Article

> Gynecological cancer vaccine enters clinical trials. More

> Research paving way to salmonella vaccine. Story

> IIL developing firsts for vaccines in India. News

> Sanofi's Shantha Biotechnics hopes to relaunch vaccine. Item

Manufacturing News

> Hospira sees dim light at end of plant troubles. Piece

> FDA inspects three Merck plants along EU supply chain. Item

CRO News

> Complete Genomics soars after it snags sequencing deal with Mayo Clinic. Story

> Charles River sees signs of growth in latest assessment. More

> Quintiles to offer guidance on navigating Asian drug projects. News

> Ockham adds international oncology CRO ops in Nexus buyout. Article

> Report: Catalent wants $400M loan to back Aptuit unit buyout. Item

And Finally... Will resistant gonorrhea be the last push U.S. officials need to incentivize antibiotics development? Report

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.